Table 4.
Overall concordance between Deeplex Myc-TB and phenotypic DST.
| Drug | Total | Concordant (culture-positive clinical samples/strains) | % (culture-positive clinical samples/strains) | Negative amplification by Deeplex Myc-TB | Discordant results or uncharacterized mutations by Deeplex Myc-TB a |
|---|---|---|---|---|---|
| Rifampicin | 133 | 119 (37/82) | 89.5 (84/92) | 2 | 12 |
| Isoniazid | 133 | 122 (40/82) | 92 (90/92) | 2 | 9 |
| MDR | 75 | 69 (23/46) | 92 (92/92) | 0 | 6 |
| Ethionamide | 80 | 44 (16/28) | 55 (64/51) | 1 | 35 b |
| Pyrazinamide | 104 | 88 (27/61) | 84.5 (93/81) | 1 | 15 |
| Ethambutol | 130 | 106 (37/69) | 81.5 (84/80) | 1 | 23 c |
| Fluoroquinolones | 120 | 112 (28/84) | 93 (87.5/95) | 1 | 7 |
| Kanamycin/amikacin | 86 | 74 (25/49) | 86 (86/86) | 1 | 11 d |
| Capreomycin | 83 | 80 (25/55) | 96.5 (96/96.5) | 1 | 2 |
| Streptomycin | 128 | 94 (32/62) | 73 (78/72) | 1 | 33 e |
| Linezolid | 84 | 79 (23/56) | 94 (88/96.5) | 3 | 2 f |
| Bedaquiline | 83 | 76 (22/54) | 91.5 (88/93) | 1 | 6 g |
Mutations detailed on Supplementary Table 1 .
Including one discrepancy between a -15 c->t mutation in the inhA promoter and the ETH-S DST result for one strain.
Including 11 EMB-R-conferring mutations giving discrepant results (EMB-S) with DST (M306I, G406A or D, D354A, Q497R, S297A, and Y319S).
Including four discrepancies between Deeplex Myc-TB and DST at the level of the eis promoter positions -10g->a (n = 1), -14c->t (n = 1), and -37g->t (n = 2), and 5 in rrs at position c1402t (n = 1), c517t (n = 2), and a906g (n = 2).
Including 28 uncharacterized mutations.
Two LNZ-R strains with no detectable mutations in rrl nor in rplC.
Including two discrepancies observed in one BDQ-R strain with a frameshift not detected by Deeplex Myc-TB, and one BDQ-S strain harboring a E55D substitution in Rv0678.